Patients with locoregionally advanced nasopharyngeal carcinoma (NPC) typically receive induction chemotherapy followed by concurrent chemoradiotherapy. Nonetheless, 20–30% of patients will have disease progression on this regimen and, given the high level of PD-L1-positivity typically seen in this cancer type, an important question exists regarding the possibility of benefit from anti-PD-1 or anti-PD-L1 antibodies in this setting. Now, data from the phase III CONTINUUM trial demonstrate the efficacy of adding the anti-PD-1 antibody sintilimab to standard treatment.

A total of 425 patients with newly diagnosed, stage III–IVa NPC were randomly assigned (1:1) to four cycles of gemcitabine–cisplatin followed by concurrent cisplatin plus radiotherapy with versus without up to 12 cycles of sintilimab starting during induction. Event-free survival (EFS) was the primary end point.

局部晚期鼻咽癌（NPC）患者通常接受诱导化疗，然后同步放化疗。尽管如此，20-30% 的患者在此方案中会出现疾病进展，并且考虑到这种癌症类型中常见的高水平 PD-L1 阳性，存在一个重要问题，即抗 PD-1 或在这种情况下，抗 PD-L1 抗体。现在，来自 III 期 CONTINUUM 试验的数据证明了在标准治疗中添加抗 PD-1 抗体信迪利单抗的功效。

共有 425 名新诊断的 III-IVa 期 NPC 患者被随机分配 (1:1) 接受 4 个周期的吉西他滨-顺铂治疗，然后同时进行顺铂加放疗，并在诱导期间开始使用最多 12 个周期的信迪利单抗。无事件生存期（EFS）是主要终点。